Vitae Pharmaceuticals Company Profile

10:59 EST 26th November 2015 | BioPortfolio

Vitae Pharmaceuticals is an emerging pharmaceutical company with two compounds in human clinical trials, a broad portfolio of late stage preclinical programs and an underlying pipeline of discovery programs. Vitae's goal is to discover, develop and commercialize innovative new medicines that will be best-in-class for important disease areas, such as cardiovascular diseases, cancer and dermatology.We are focused on the development of compounds for high value, well validated biological targets. In our discovery and development processes, we seek to leverage available existing clinical and / or preclinical knowledge to efficiently and effectively create novel drug candidates that can address clear unmet therapy needs. Vitae's unique product engine combines the drug discovery skills of proven, deeply experienced drug hunters with state-of-the-art proprietary drug design technologies. This integrated and entrepreneurial approach improves the quality and innovativeness of the compounds we discover, while dramatically shortening the time required to bring them to the clinic.We have demonstrated the ability to rapidly advance novel compounds into clinical development, as Vitae now has clinical candidates in three therapeutic areas, two of which are in clinical studies and a pipeline of additional promising compounds.


502 West Office Center
Drive Fort Washington
United States of America


Phone: (215) 461-2000
Fax: (215) 461-2006

News Articles [45 Associated News Articles listed on BioPortfolio]

Stunned Vitae undeterred by BI backout

Vitae Pharmaceuticals took another hit on 27 July, in what its CEO termed some "unforeseen news." The surprise announcement was that its big pharma partner, Boehringer Ingelheim, has pulled out of ano...

Vitae gains on Phase I data for VTP-43742

Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) gained $7.06 (89%) to $14.99 after it announced safety and biomarker results from a Phase I study of VTP-43742 to treat autoimmune diseases. Vitae said an ex v...

Vitae/Boehringer's diabetes drug fails in metformin arm of Phase II trial

Clinical-stage biotech company Vitae Pharmaceuticals has announced that its drug BI187004/VTP-34072 failed…

Boehringer terminates Vitae BACE deal

Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) dropped $0.70 to $9.68 after it said Boehringer Ingelheim GmbH (Ingelheim, Germany) will terminate for "strategic business reasons" a 2009 licensing deal for V...

Boehringer Ingelheim and Vitae type 2 diabetes drug misses endpoint

Vitae has announced top-line efficacy results from the metformin arm of a trial of BI187004/VTP-34072 in the treatment of patients with type 2 diabetes... The post Boehringer Ingelheim and Vitae type ...

Boehringer pulls out of deal with Vitae Pharma for BACE Inhibitors

Vitae Pharmaceuticals today announced that German family-owned pharma major Boehringer Ingelheim is ending…

Forget diabetes, Vitae looks to MS drug

Investors showed their disappointment in results from Vitae Pharmaceuticals' diabetes drug, but the company sees the recent data release as just one of several catalysts that is expected this year. Ye...

Vitae-Boehringer diabetes drug fails as add-on therapy in trial

June 29 (Reuters) - Vitae Pharmaceuticals Inc said its drug to treat type 2 diabetes in overweight patients did not meet its main goal in a mid-stage study testing it as an add-on therapy.

Drugs and Medications [0 Results]


PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Preparing for Fellowship in Internal Medicine: Steps for Success with a Focus on Pulmonary and/or Critical Care Programs.

This paper outlines specific tips for those applying to pulmonary and/or critical care medicine fellowship training in the United States utilizing the PAIR-Match steps: Preparation, Application, Inter...

A Spatiotemporal Analysis of Brazilian Science from the Perspective of Researchers' Career Trajectories.

The growth of Brazilian scientific production in recent years is remarkable, which motivates an investigation on the factors, inside and outside the country, that helped shape this wealthy research en...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)

The aim of the study is to evaluate toxicity and effectiveness of electrochemotherapy with bleomycin in treatment of primary liver tumors in clinical study phase I and II. The study will ...

Companies [7 Associated Companies listed on BioPortfolio]

Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals is a development-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address large markets, including...

Vitae Pharmaceuticals

Vitae Pharmaceuticals is an emerging pharmaceutical company with two compounds in human clinical trials, a broad portfolio of late stage preclinical programs and an underlying pipeline of discovery pr...

CV Index

The CV Index provides a permanent, web presence & management centre for your Curriculum Vitae (Resume), which is freely searchable on our powerful CVs search engine, wherever you are in the world. Ch...


Our Profile represents an introductory overview of the key facts investors need to know about BB MEDTECH. The various ticker symbols are also available here. Click on Board of Directors and Management...

BitTech, Inc

BitTech, Inc. is a biotechnology company that focuses on the identification and initiation of research which has the potential to lead to enabling technology. BitTech was founded by Grant A. Bitter, ...

More Information about "Vitae Pharmaceuticals" on BioPortfolio

We have published hundreds of Vitae Pharmaceuticals news stories on BioPortfolio along with dozens of Vitae Pharmaceuticals Clinical Trials and PubMed Articles about Vitae Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Vitae Pharmaceuticals Companies in our database. You can also find out about relevant Vitae Pharmaceuticals Drugs and Medications on this site too.


Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Corporate Database Quicklinks

Searches Linking to this Company Record